本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 下简称"公司"）及公司下属子公司累计收到各类政府补助共计人民币 2,885.28 万 元（数据未经审计）。其中，与收益相关的政府补助 1,448.08 万元，占公司最近 一个会计年度经审计的归属于上市公司股东净利润的比例为 19.55%；与资产相 关的政府补助 1,437.20 万元，占公司最近一个会计年度经审计的归属于上市公司 股东净资产的比例为 0.18%。 证券代码：603127 证券简称：昭衍新药 公告编号：2025-033 北京昭衍新药研究中心股份有限公司 关于获得政府补助的公告 二、补助的类型及其对公司的影响 公司根据《企业会计准则第 16 号--政府补助》的有关规定确认上述事项， 并划分补助类型。上述与收益相关的政府补助计入其他收益 1,448.08 万元，预计 对 2025 年损益影响的金额为 1,242.99 万元（数据未经审计）；与资产相关的政 府补助确认为递延收益的政府补助金额为 1,437.20 万元，自相关资产可供使用时 起，按照 ...

Summary of Key Points Core Viewpoint - The company has announced the provision for asset impairment for the first half of 2025, reflecting a need to accurately represent its financial status and operational results as of June 30, 2025 [1][2]. Group 1: Asset Impairment Provision Overview - The company conducted impairment testing on various assets as of June 30, 2025, resulting in a total asset impairment provision of 60.6191 million RMB [1]. - The breakdown of the impairment losses includes a credit impairment loss of 5.3914 million RMB and an asset impairment loss of 66.0105 million RMB [1]. Group 2: Specifics of the Impairment Provision - The company recognized impairment losses based on expected credit losses for accounts receivable, contract assets, and other receivables, leading to a total provision for bad debt [1]. - The impairment loss for long-term deferred expenses amounted to 10.4693 million RMB, indicating signs of impairment as of the balance sheet date [1]. - The provision will reduce the equity attributable to shareholders by 54.1420 million RMB as of June 30, 2025, and is in compliance with relevant accounting standards and company policies [2].

（文章来源：证券日报） 证券日报网讯 8月26日晚间，昭衍新药发布公告称，2025年1月1日至本公告披露日，公司及公司下属子 公司累计收到各类政府补助共计人民币2，885.28万元（数据未经审计）。 ...

格隆汇8月26日丨昭衍新药(603127.SH)公布，2025年1月1日至本公告披露日，及公司下属子公司累计收 到各类政府补助共计人民币2,885.28万元（数据未经审计）。其中，与收益相关的政府补助1,448.08万 元，占公司最近一个会计年度经审计的归属于上市公司股东净利润的比例为19.55%；与资产相关的政 府补助1,437.20万元，占公司最近一个会计年度经审计的归属于上市公司股东净资产的比例为0.18%。 ...

Core Viewpoint - Zhaoyan New Drug (603127.SH) is establishing a seed fund in collaboration with investment management firms to focus on strategic emerging industries, particularly in biomedicine and high-end medical devices [1] Group 1 - The company plans to sign a partnership agreement with Yifeng Capital and Yifeng Mingyuan Technology to set up the Shenzhen Yifeng Guangming Science City Seed Fund [1] - The fund will target investments in industries supported by the Shenzhen government, emphasizing biomedicine and high-end medical devices [1] - The company or its designated subsidiary will contribute no more than 10 million RMB as a limited partner in the fund [1]

Core Viewpoint - The company is establishing a seed fund in collaboration with professional investment institutions to invest in strategic emerging industries, particularly in the biomedicine and high-end medical equipment sectors [1][2]. Group 1: Fund Establishment - The company, along with its designated subsidiaries, plans to sign a partnership agreement to establish the Shenzhen Yifeng Guangming Science City Seed Fund, with a maximum investment of 10 million RMB [1]. - The fund aims to support and develop strategic emerging industries and other key industries promoted by the Shenzhen government [1]. Group 2: Strategic Alignment - This investment aligns with the company's long-term development strategy and will leverage the resources and expertise of its partners to broaden investment channels [2]. - The collaboration is expected to provide momentum and assurance for the company's sustainable high-quality development [2]. Group 3: Risk Management - The company will benefit from the management experience and risk control systems of the fund managers, which will help mitigate investment risks and ensure project quality [2]. - The investment is not expected to have a significant adverse impact on the company's operations or performance, and it does not involve management changes or create competition [2].

Core Insights - The company reported a revenue of approximately 669 million, representing a year-on-year decrease of 21.3% [1] - Gross profit was about 105 million, down 50.3% year-on-year [1] - Net profit was 60.93 million, marking a turnaround from a loss to profit [1] - Earnings per share stood at 0.08 [1] Revenue and Profit Analysis - The decline in revenue is primarily attributed to intensified competition leading to a decrease in project unit prices [1] - The increase in net profit is mainly due to changes in the fair value of biological assets [1] - The company recognized a gain of 95 million from the fair value changes of biological assets during the period [1] Biological Assets Performance - For the six months ending June 30, 2025, the gains from biological assets were driven by natural growth [1] - In contrast, for the six months ending June 30, 2024, the company reported a loss of 254.4 million, primarily due to a decrease in the unit fair value of biological assets, consistent with the decline in market prices of experimental models [1]

Core Viewpoint - Zhaoyan New Drug (06127) announced that it has received a total of RMB 28.85 million in various government subsidies from January 1, 2025, to the date of this announcement, with the data being unaudited [1] Summary by Category - Government Subsidies Received - The company received a total of RMB 28.85 million in government subsidies [1] - Among these, subsidies related to income amounted to RMB 14.48 million, accounting for 19.55% of the company's audited net profit attributable to equity shareholders for the most recent fiscal year [1] - Asset-related government subsidies totaled RMB 14.37 million, representing 0.18% of the company's audited net assets attributable to equity shareholders for the most recent fiscal year [1]

Group 1 - The company announced a partnership with Yifeng Capital and related parties to establish a seed fund focused on strategic emerging industries, particularly in biomedicine and high-end medical devices [1][2] - The company plans to invest up to 10 million RMB in the fund, which aligns with its long-term development strategy and aims to leverage the expertise of professional investment institutions [1][2] - The investment is expected to enhance the company's investment channels and support sustainable high-quality development without significantly impacting its operations or financial performance [2] Group 2 - The partnership is designed to utilize the management experience and risk control systems of the fund managers, which will help mitigate investment risks and ensure project quality [2] - The investment will not lead to management changes, personnel adjustments, land leasing issues, or create any competition within the industry [2]

昭衍新药（603127）(06127)发布公告，集团自2025年1月1日至本公告披露日累计收到各类政府补助共 计人民币2885.28万元(数据未经审计)。 其中，与收益相关的政府补助1448.08万元，占公司最近一个会计年度经审计的归属于公司权益股东净 利润的比例为19.55%;与资产相关的政府补助1437.2万元，占公司最近一个会计年度经审计的归属于公 司权益股东净资产的比例为0.18%。 ...